You are about to leave the Clinical Value website now.


The right tools at the right time: Liquid Biopsy enters the clinic

The field of clinical oncology continues to see drastic advancements with non-invasive techniques, such as liquid biopsy being adopted for diagnosing and monitoring cancers in place of more invasive methods. Liquid biopsies consist of isolating tumor-derived entities like circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc., present in the body fluids of patients with cancer. Liquid biopsies have the potential to change the diagnostic and prognostic landscape for cancer genotyping and impact patient management. However, several limitations still hamper the implementation of liquid biopsy in clinical practice. Register to learn how liquid biopsies may help with treatment selection and monitoring of cancer treatment outcomes and the current challenges limiting clinical practice adoption.


Dr. Stephen Wong

Head of the Cancer Genomics Translational Research Centre, Peter MacCallum Cancer Centre, Australia


Prof. Natasha Leighl

Thoracic Medical Oncology Group Lead, Princess Margaret Cancer Centre, Canada

Professor, Department of Medicine, Adjunct Professor, Institute of Health Policy, Management and Evaluation University of Toronto, Canada

Dr. Lavinia Tan

Medical Oncologist, Peter MacCallum Cancer Centre, Australia


This content is targeted at healthcare professionals and could contain information otherwise not accessible, approved or valid in your country. Please be aware that we do not take any responsibility for you accessing information which may not comply with any legal process, regulation, registration or usage in the country of your origin.This content is for general information purposes only. We disclaim all liability and are not responsible for any third party content on our website or which our website links to.

Be the first to receive updates, event opportunities, and thought leadership insights.